<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35221703</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1178-7015</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>15</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Clinical, cosmetic and investigational dermatology</Title>
          <ISOAbbreviation>Clin Cosmet Investig Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria.</ArticleTitle>
        <Pagination>
          <StartPage>261</StartPage>
          <EndPage>270</EndPage>
          <MedlinePgn>261-270</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/CCID.S350122</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Though second-generation antihistamines (SGAH) are first-line drugs in chronic spontaneous urticaria (CSU), 50% of patients do not respond to them. In such patients, guidelines recommend either up-dosing of SGAH or combination of different antihistamines. However, the studies comparing these treatment regimens are limited.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this comparative, three-arm study, CSU patients were randomized to receive standard dose of either bilastine, fexofenadine, or levocetirizine for 2 weeks. After 2 weeks of treatment, non-responders received double dose of either bilastine or fexofenadine, while hydroxyzine 25 mg once daily was added in the levocetirizine group. Patients were primarily evaluated for improvement in CSU, quality of life, and somnolence.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 110 patients with CSU were recruited. At the end of 4 weeks, 33/39, 26/35, and 22/36 patients in the bilastine, fexofenadine, and levocetirizine groups showed improvement in urticaria symptoms. At week 2, there was no statistical difference in urticaria activity score (UAS7) improvement between any of the groups; however, at week 4, there was a statistical difference between the bilastine and levocetirizine groups (<i>p</i>&lt;0.05). Somnolence was significantly lower in the bilastine group (<i>p</i>&lt;0.05). Bilastine was statistically significant (<i>p</i>&lt;0.05) in the improvement of quality of life as compared to both groups. No major adverse events were reported during study period; however, bilastine was associated with significantly lower levels of AEs compared to levocetirizine (<i>p</i>&lt;0.05).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Two-fold up-dosing of bilastine improves CSU symptoms without compromising safety as compared to two-fold up-dosing of fexofenadine and combination of first- and second-generation antihistamines.</AbstractText>
          <CopyrightInformation>© 2022 Shah et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Bela</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, B.J.Medical College, Civil Hospital, Ahmedabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dhoot</LastName>
            <ForeName>Dhiraj</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-2045-9324</Identifier>
            <AffiliationInfo>
              <Affiliation>DGM, Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choudhary</LastName>
            <ForeName>Ankita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, B.J.Medical College, Civil Hospital, Ahmedabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jangid</LastName>
            <ForeName>Neha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, B.J.Medical College, Civil Hospital, Ahmedabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mistry</LastName>
            <ForeName>Deval</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, B.J.Medical College, Civil Hospital, Ahmedabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Shikha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, B.J.Medical College, Civil Hospital, Ahmedabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamat</LastName>
            <ForeName>Shruti</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, B.J.Medical College, Civil Hospital, Ahmedabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barkate</LastName>
            <ForeName>Hanmant</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Cosmet Investig Dermatol</MedlineTA>
        <NlmUniqueID>101543449</NlmUniqueID>
        <ISSNLinking>1178-7015</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">bilastine</Keyword>
        <Keyword MajorTopicYN="N">chronic spontaneous urticaria</Keyword>
        <Keyword MajorTopicYN="N">fexofenadine</Keyword>
        <Keyword MajorTopicYN="N">hydroxyzine</Keyword>
        <Keyword MajorTopicYN="N">levocetirizine</Keyword>
        <Keyword MajorTopicYN="N">up dosing</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35221703</ArticleId>
        <ArticleId IdType="pmc">PMC8867222</ArticleId>
        <ArticleId IdType="doi">10.2147/CCID.S350122</ArticleId>
        <ArticleId IdType="pii">350122</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi:10.1111/all.13397</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.13397</ArticleId>
            <ArticleId IdType="pubmed">29336054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The Global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226–236. doi:10.1111/bjd.19561</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.19561</ArticleId>
            <ArticleId IdType="pubmed">32956489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197–201. doi:10.1111/j.1365-2133.1997.tb14895.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2133.1997.tb14895.x</ArticleId>
            <ArticleId IdType="pubmed">9068731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003;58(7):621–623. doi:10.1034/j.1398-9995.2003.00091.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1398-9995.2003.00091.x</ArticleId>
            <ArticleId IdType="pubmed">12823121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006;61(3):316–320. doi:10.1111/j.1398-9995.2005.00964.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1398-9995.2005.00964.x</ArticleId>
            <ArticleId IdType="pubmed">16436140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen LJ, Church MK, Skov PS. Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study. Clin Exp Allergy. 1997;27(3):284–295. doi:10.1111/j.1365-2222.1997.tb00707.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2222.1997.tb00707.x</ArticleId>
            <ArticleId IdType="pubmed">9088655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy. 2006;61(3):321–331. doi:10.1111/j.1398-9995.2005.00962.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1398-9995.2005.00962.x</ArticleId>
            <ArticleId IdType="pubmed">16436141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol. 1998;138(4):635–638. doi:10.1046/j.1365-2133.1998.02175.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2133.1998.02175.x</ArticleId>
            <ArticleId IdType="pubmed">9640369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuberbier T, Münzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193(4):324–327. doi:10.1159/000246281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000246281</ArticleId>
            <ArticleId IdType="pubmed">8993958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol. 2007;32(1):34–38. doi:10.1111/j.1365-2230.2006.02278.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2230.2006.02278.x</ArticleId>
            <ArticleId IdType="pubmed">17042777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn AF, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104(5):1071–1078. doi:10.1016/S0091-6749(99)70091-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0091-6749(99)70091-6</ArticleId>
            <ArticleId IdType="pubmed">10550755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517–522. doi:10.1016/S1081-1206(10)62515-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)62515-X</ArticleId>
            <ArticleId IdType="pubmed">10831005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing?
J Investig Allergol Clin Immunol. 2013;23(3):141–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23967751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012;4(6):326–331. doi:10.4168/aair.2012.4.6.326</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4168/aair.2012.4.6.326</ArticleId>
            <ArticleId IdType="pmc">PMC3479225</ArticleId>
            <ArticleId IdType="pubmed">23115728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869–873. doi:10.1111/j.1365-2230.2010.03840.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2230.2010.03840.x</ArticleId>
            <ArticleId IdType="pubmed">20456386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009;23(9):1088–1091. doi:10.1111/j.1468-3083.2009.03289.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-3083.2009.03289.x</ArticleId>
            <ArticleId IdType="pubmed">19453774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiragun T, Hide M. Japanese guidelines for diagnosis and treatment of urticaria. Arerugi. 2017;66(1):23–26. doi:10.15036/arerugi.66.23</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15036/arerugi.66.23</ArticleId>
            <ArticleId IdType="pubmed">28216532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277. doi:10.1016/j.jaci.2014.02.036</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2014.02.036</ArticleId>
            <ArticleId IdType="pubmed">24766875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol. 2000;85(6 Pt 2):521–544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11190256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grattan CE, Humphreys F; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol. 2007;157(6):1116–1123. doi:10.1111/j.1365-2133.2007.08283.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2133.2007.08283.x</ArticleId>
            <ArticleId IdType="pubmed">18021095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5):631–650. doi:10.1111/j.1365-2222.2007.02678.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2222.2007.02678.x</ArticleId>
            <ArticleId IdType="pubmed">17456211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staevska M, Gugutkova M, Lazarova C, et al. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol. 2014;171(1):148–154. doi:10.1111/bjd.12846</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.12846</ArticleId>
            <ArticleId IdType="pmc">PMC4232862</ArticleId>
            <ArticleId IdType="pubmed">24472058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izumi N, Mizuguchi H, Umehara H, Ogino S, Fukui H. Evaluation of efficacy and sedative profiles of H(1) antihistamines by large-scale surveillance using the visual analogue scale (VAS). Allergol Int. 2008;57(3):257–263. doi:10.2332/allergolint.O-07-525</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2332/allergolint.O-07-525</ArticleId>
            <ArticleId IdType="pubmed">18566547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollis K, Proctor C, McBride D, et al. Comparison of urticaria activity score over 7 days (UAS7) values obtained from once-daily and twice-daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol. 2018;19(2):267–274. doi:10.1007/s40257-017-0331-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40257-017-0331-8</ArticleId>
            <ArticleId IdType="pmc">PMC5978890</ArticleId>
            <ArticleId IdType="pubmed">29368043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60(8):1073–1078. doi:10.1111/j.1398-9995.2005.00833.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1398-9995.2005.00833.x</ArticleId>
            <ArticleId IdType="pubmed">15969690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiragun M, Hiragun T, Mihara S, Akita T, Tanaka J, Hide M. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy. 2013;68(2):229–235. doi:10.1111/all.12078</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.12078</ArticleId>
            <ArticleId IdType="pubmed">23205732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Podder I, Das A, Ghosh S, Biswas D, Sengupta S, Chowdhury SN. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: a double-blind, parallel group, randomized controlled trial. Dermatol Ther. 2020;33(6):e13946. doi:10.1111/dth.13946</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dth.13946</ArticleId>
            <ArticleId IdType="pubmed">32618048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah B, De A, Sarda A, et al. Effect of bilastine on chronic spontaneous urticaria refractory to levocetrizine: real world experience in India. Dermatol Ther. 2021;34(1):e14557. doi:10.1111/dth.14557</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dth.14557</ArticleId>
            <ArticleId IdType="pubmed">33210404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godse KV, Nadkarni NJ, Jani G, Ghate S. Fexofenadine in higher doses in chronic spontaneous urticaria. Indian Dermatol Online J. 2010;1(1):45–46. doi:10.4103/2229-5178.73262</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2229-5178.73262</ArticleId>
            <ArticleId IdType="pmc">PMC3481404</ArticleId>
            <ArticleId IdType="pubmed">23130196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65(4):516–528. doi:10.1111/j.1398-9995.2009.02217.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1398-9995.2009.02217.x</ArticleId>
            <ArticleId IdType="pubmed">19860762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagami A, Furue M, Togawa M, Saito A, Hide M. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44(4):375–385. doi:10.1111/1346-8138.13644</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1346-8138.13644</ArticleId>
            <ArticleId IdType="pmc">PMC5412823</ArticleId>
            <ArticleId IdType="pubmed">27862227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Borges M, Ansotegui I, Jimenez JM, Rojo MI, Serrano C, Yañez A. Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria. World Allergy Organ J. 2014;7(1):33. doi:10.1186/1939-4551-7-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1939-4551-7-33</ArticleId>
            <ArticleId IdType="pmc">PMC4363057</ArticleId>
            <ArticleId IdType="pubmed">25829981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68(7):921–928. doi:10.1111/all.12171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.12171</ArticleId>
            <ArticleId IdType="pmc">PMC3759706</ArticleId>
            <ArticleId IdType="pubmed">23742030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weller K, Church MK, Hawro T, et al. Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: a real-life study. Allergy. 2018;73(10):2073–2075. doi:10.1111/all.13494</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.13494</ArticleId>
            <ArticleId IdType="pubmed">29869790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weller K, Viehmann K, Bräutigam M, et al. Management of chronic spontaneous urticaria in real life–in accordance with the guidelines? A cross-sectional physician-based survey study. J Eur Acad Dermatol Venereol. 2013;27(1):43–50. doi:10.1111/j.1468-3083.2011.04370.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-3083.2011.04370.x</ArticleId>
            <ArticleId IdType="pubmed">22150693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol. 2009;123(3):713–717. doi:10.1016/j.jaci.2008.10.050</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2008.10.050</ArticleId>
            <ArticleId IdType="pubmed">19081615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van den Elzen MT, van Os-medendorp H, van den Brink I, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy. 2017;7:4. doi:10.1186/s13601-017-0141-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13601-017-0141-3</ArticleId>
            <ArticleId IdType="pmc">PMC5309999</ArticleId>
            <ArticleId IdType="pubmed">28289538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordness M, Zacharisen MC. High dose cetirizine: a case report. Cutis. 2003;71(5):396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12769407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22(5):511–515. doi:10.1097/00004714-200210000-00012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004714-200210000-00012</ArticleId>
            <ArticleId IdType="pubmed">12352276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic [published correction appears in Ann Allergy Asthma Immunol. 2004 Jun; 92(6):675][published correction appears in Ann Allergy Asthma Immunol. 2005 Mar;94(3):409–410]. Ann Allergy Asthma Immunol. 2004;92(3):294–355. doi:10.1016/S1081-1206(10)61566-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)61566-9</ArticleId>
            <ArticleId IdType="pubmed">15049392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Gea C, Martínez-Colomer J, Antonijoan RM, Valiente R, Barbanoj MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008;28(6):675–685. doi:10.1097/JCP.0b013e31818b2091</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0b013e31818b2091</ArticleId>
            <ArticleId IdType="pubmed">19011437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676–682. doi:10.1016/j.jaci.2009.11.047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.11.047</ArticleId>
            <ArticleId IdType="pubmed">20226302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farré M, Pérez-Mañá C, Papaseit E, et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol. 2014;78(5):970–980. doi:10.1111/bcp.12421</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.12421</ArticleId>
            <ArticleId IdType="pmc">PMC4243871</ArticleId>
            <ArticleId IdType="pubmed">24833043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons FE, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. J Allergy Clin Immunol. 1984;73(1 Pt 1):69–75. doi:10.1016/0091-6749(84)90486-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0091-6749(84)90486-X</ArticleId>
            <ArticleId IdType="pubmed">6141198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra E, Campo C, Novák Z, et al. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study. J Dermatolog Treat. 2020;31(3):270–278. doi:10.1080/09546634.2019.1590522</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09546634.2019.1590522</ArticleId>
            <ArticleId IdType="pubmed">30835579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godse K, De A, Zawar V, et al. Bilastine for the treatment of chronic spontaneous urticaria: consensus statement for Indian patients. Indian J Clin Exp Dermatol. 2019;5(3):180–185. doi:10.18231/j.ijced.2019.039</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18231/j.ijced.2019.039</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
